Sepracor, Inc. (NASDAQ: SEPR), a research-based pharmaceutical company, has focused their efforts on treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products designed to serve large and growing markets. The company’s drug development program has proven its success by yielding a portfolio of pharmaceutical products and candidates. The focus of the program is on treating respiratory and central nervous system (CNS) disorders. For further information, visit the Company’s web site at www.sepracor.com.
- 17 years ago
QualityStocks
Sepracor, Inc. (NASDAQ: SEPR)
Tags Rodman & Renshaw
Related Post
-
Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ): Positioned at the Center of U.S. Copper Security and Policy
The White House’s recent proclamation targets copper imports with tariffs to bolster domestic production and…
-
SuperCom Ltd. (NASDAQ: SPCB) Expands U.S. Footprint with New Wisconsin Project, 12th State in One Year
SuperCom has secured a new electronic monitoring project with a sheriff’s department in Wisconsin, marking…
-
FDA Guidance Sets Lantern Pharma Inc. (NASDAQ: LTRN) On a Path Toward Realizing Its Clinical Trial Plans for Rare Pediatric Cancer Therapy
Texas-based clinical-stage biotechnology company Lantern Pharma Inc. is developing a number of clinical trials, using…